Are we victims of our own success in cardiovascular therapeutics? Afshin Farzaneh-FarPeter Libby Invited Commentary Pages: 1 - 2
Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important? Tracie C. CollinsPeter H. Jones OriginalPaper Pages: 10 - 17
Statin therapy in renal disease: Harmful or protective? Peter A. McCulloughLeslie R. Rocher OriginalPaper Pages: 18 - 24
Statin therapy in cardiovascular diseases other than atherosclerosis Dominique BeaudryKenneth E. StoneRobert Chilton OriginalPaper Pages: 25 - 32
Statins and biomarkers of inflammation Sridevi DevarajJason RogersIshwarlal Jialal OriginalPaper Pages: 33 - 41
Will torcetrapib be the next big thing in coronary heart disease risk reduction? James M. McKenneyJohn A. Hoekstra OriginalPaper Pages: 48 - 56
Modifying the anti-inflammatory effects of high-density lipoprotein Benjamin J. AnsellGregg C. FonarowAlan M. Fogelman OriginalPaper Pages: 57 - 63
Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE Jennifer G. Robinson OriginalPaper Pages: 64 - 71
Squalene synthase inhibition: A novel target for the management of dyslipidemia Michael H. Davidson OriginalPaper Pages: 78 - 80
Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol Peter P. Toth OriginalPaper Pages: 81 - 88